Crown Bioscience Increases APAC Capacity with New Facility in Zhongshan, China
Crown Bioscience, a JSR Life Sciences company, today announces the opening of a new oncology-focused research facility in Zhongshan, China to satisfy increased customer demand.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201027005098/en/
In addition to the Company’s four facilities across the US and Europe, CrownBio’s existing APAC footprint currently includes three sites located in Beijing, Taicang, and Suzhou, as well as one in Taiwan. Once completed, this new building will add more than 2,000m2 of new vivarium space to support CrownBio’s in vivo oncology platforms, helping satisfy predicted near-term growth.
CrownBio’s world-leading products and services are used by pharmaceutical and biotech customers across APAC, North America, and Europe to accelerate and de-risk their drug discovery programs. With the significant and continued growth of CrownBio’s client base, the Zhongshan facility has been purpose built to meet expanding study needs.
The research and drug development facility features BSL-2 laboratories and will include a state-of-the-art ABSL-2 vivarium. Initial capabilities will focus on expanding cell line-derived xenograft model availability and study throughput, with an increased roster of cutting edge, translational oncology models becoming available. Full operational capacity is expected in early 2021.
“The establishment of our new Zhongshan facility demonstrates our continued commitment to our clients, to provide sustained rapid study initiation combined with robust cost-effectiveness,” said John Gu, chief operating officer at CrownBio. “Through our growth, we can more fully support our clients in their goals of more rapid and efficient cancer drug development”.
A site opening event and ribbon cutting ceremony will take place on October 30th 2020.
About Crown Bioscience Inc.
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, inflammation, and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates. For more information, visit:
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AZ-2J-ANTENNAS23.9.2021 16:52:13 CEST | Press release
2J Antennas Launches The World’s Smallest 5GNR, WiFi-6E and GNSS Combination 9-in-1 Antennas For Critical Communication Modernization
PA-SALADAX-BIOMEDICAL23.9.2021 16:07:07 CEST | Press release
Saladax Biomedical Announces Salvatore J. Salamone, Ph.D. Received the Prestigious Dr. C.E. Pippenger Award
CA-CEPTON-TECHNOLOGIES23.9.2021 16:02:06 CEST | Press release
Belam and Cepton Establish Partnership to Enable Safety at High-traffic Railway Level Crossings
MA-HARBOURVEST23.9.2021 16:02:06 CEST | Press release
HarbourVest Partners Announces Close of Direct Lending Fund
OR-NUSCALE-POWER23.9.2021 15:47:14 CEST | Press release
NuScale Power Signs Memorandum of Understanding with KGHM and PBE to Explore SMR Deployment in Poland
ALLEGRO-DVT23.9.2021 15:37:09 CEST | Press release
Allegro DVT and Beamr Announce the World’s First Content-Adaptive Silicon IP Video Encoder
NEXO23.9.2021 15:32:09 CEST | Press release
Nexo Passes Real-Time Reserves Audit Conducted by Armanino
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom